The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
Healthcare giant Pfizer ( PFE 2.24%) has been offering a high yield for some time. But that hasn't been enough to get ...
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded ...
Pfizer and manufacturer Tris Pharma have agreed to hand over $41.5 million to lay to rest a 2023 lawsuit accusing the ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
12don MSN
Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition
Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...
Pfizer and Tris Pharma will pay $41.5 million to settle allegations they provided an ADHD medicine knowing about “flawed” manufacturing practices ...
Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...
Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...
11don MSN
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...
Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...
Pfizer and Tris Pharma agreed to pay $41.5 million to settle allegations they altered testing methods to ensure their ADHD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results